Octreotide Efficacy and Safety in First-line Acromegalic Patients

Inclusion Criteria: * Males and females 18 and \< 80 years old. * Recently diagnosed not previously treated patients with acromegaly. * Presence of a pituitary tumor (microadenoma or macroadenoma), documented by a MNR performed in the 12 weeks before enrolment. * Absence of nadir suppression of the nadir of GH to \< 1.0 ng/mL, after oral administration of 75 g of glucose (OTTG). * IGF-I levels over normal upper limits, e.g. 97 percentile (age- and sex-matched). * Tolerance shown with a test of a subcutaneous injection of octreotide * Written Informed Consent before any procedure specific to the study. Inclus Exclusion Criteria: * Previously treated patients with any therapy for acromegaly, including surgery, radiotherapy, bromocriptin, and somatostatin analogues. * Compression of optic chiasm that produces any impairment of field of vision. * Need of surgery to improve any neurological sign or symptom associated with a direct incidence on the tumour. * Intolerance to octreotide or to any component of Sandostatin® LAR® preparation. * Patients with an hepatic condition such as cirrhosis, active or persisting chronic hepatitis, or other hepatopathy of fast evolution. * Pregnant women * History of alcohol or drug abuse in the six months prior to the inclusion visit. * Patients suffering from any condition that may jeopardize the interpretation of study results or may impede to obtain informed consent * Intake of an investigational drug during the study and 30 days before patient inclusion in this study Other protocol-defined inclusion / exclusion criteria may apply.